RT Journal Article SR Electronic T1 The Omega-3 Index is Inversely Associated with the Neutrophil-Lymphocyte Ratio in Adults JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.22.21264656 DO 10.1101/2021.10.22.21264656 A1 Michael I. McBurney A1 Nathan L. Tintle A1 William S. Harris YR 2021 UL http://medrxiv.org/content/early/2021/12/14/2021.10.22.21264656.abstract AB The neutrophil-lymphocyte ratio (NLR) is a biomarker of systemic inflammation and measures innate-adaptive immune system balance. The omega-3-index (O3I) measures the amount of EPA+DHA in blood. Both a low O3I and an elevated NLR are associated with increased risk for chronic disease and mortality, including cardiovascular diseases and cancer. Hypothesizing that low O3I may partly contribute to systemic chronic inflammation, we asked if a relationship existed between O3I and NLR in healthy adults (≥18y, n=28,871, 51% female) without inflammation [C-reactive protein (CRP) <3mg/mL)] who underwent a routine clinical assessment. NLR was inversely associated with O3I before (p<0.0001) and after adjusting for age, sex, BMI, and CRP (p<0.0001). Pearson correlations of other variables with NLR were r=0.06 (CRP), r=0.14 (age), and r=0.01(BMI). In this healthy population, an O3I <6.6% was associated with increasing NLR whereas NLR remained relatively constant (low) when O3I >6.6%, suggestive of a quiescent, balanced immune system.Competing Interest StatementM.I. McBurney serves on the Board of Directors of the American Society for Nutrition and has or has held consulting agreements in the past 3 years with Council for Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences Institute, North America; McCormick; OmegaQuant Analytics; PepsiCo; and VitaMe Technologies. W.S. Harris holds an interest in OmegaQuant Analytics, a lab that offers omega-3 blood testing; and is a member of the RB Schiff Science and Innovation Advisory Board. N.L. Tintle has no conflicts to disclose.Funding StatementThis work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of South Dakota Institutional Review Board reviewed and approved the use of such de-identified clinical data for research purposes (IRB-21-147).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPending application and approval, data described in the manuscript, code book, and analytic code will be made available upon request to the Fatty Acid Research Institute. https://www.faresinst.org/ BMIbody mass indexCRPhigh-sensitivity C-reactive proteinDHAdocosahexaenoic acidEPAeicosapentaenoic acidNLRneutrophil-lymphocyte ratioO3Iomega-3 indexSPMspecialized pro-resolving lipid mediators.